11th July 2022 | Pharma Updates
Aurobindo Pharma on pace to develop complex products and increase its global presence
Aurobindo Pharma is still concentrating on creating complex and distinctive medicines across a variety of industries, including oncology, hormonal products, biosimilars, depot injections, and vaccines, to propel the company into the next stage of growth.
Delhi's I-T Department conducts property raids at pharma companies and seizes $4 million
Raids were conducted by the Income Tax (I-T) Department against a group involved in the production and distribution of pharmaceutical drugs, as well as real estate development. The raid took place on June 29. 25 locations in Delhi-NCR and Haryana were searched.
Centre releases the draft New Drugs, Medical Devices, and Cosmetics Bill, 2022
In order to keep up with changing needs, times, and technology in comparison to the pre-independence legislation of the Drugs and Cosmetics Act, 1940, the Union ministry of health and family welfare has released the draft of the New Drugs, Medical Devices, and Cosmetics Bill, 2022.
Strengthening quality compliance in pharma firms: Piramal
As per Piramal Enterprises Ltd Chairman Ajay G Piramal, pharmaceutical companies with a solid track record of quality compliance and the ability to adapt to new regulatory needs would grow stronger as the impact of the pandemic lessens.
Glenmark Pharma introduces a type 2 diabetes drug in India
The launch of sitagliptin and its fixed dose combinations (FDCs) for individuals with Type-2 diabetes in India was announced by Glenmark. The company has made available 8 various combinations of sitagliptin-based medications at reasonable prices.
NPPA instructs Neon Laboratories to continue producing Tropine injectable for additional 6 months
National Pharmaceutical Pricing Authority has made the decision to further extend its directive to Mumbai-based Neon Laboratories to continue producing atropine injection 0.6 mg/ml, a medication used to treat bradycardia.
Due to graft case, Biocon arm Syngene terminates contract with Bioinnovat Research
The promoter of Bioinnovat Research Services, who was cited in the anti-graft lawsuit, has been separated from Syngene International. The business recently ended its retainer consultancy agreement with Bioinnovat.
